Yazar "İlhan, Osman" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome–positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up
    (Taylor and Francis Ltd., 2018) Saydam, Güray; Haznedaroğlu, İbrahim Celalettin; Kaynar, Leylagül; Yavuz, Akif S.; Ali, Rıdvan; Güvenç, Birol; Akay, Olga M.; Başlar, Zafer; Özbek, Uğur; Sönmez, Mehmet; Aydın, Demet; Pehlivan, Mustafa; Ündar, Bulent; Dağdaş, Simten; Ayyıldız, Mehmet Orhan; Akın, Gülnur; Dağ, İlkiz M.; İlhan, Osman
    bjectives: This report presents final results (24 months of follow-up) from the first prospective, national study of frontline nilotinib in chronic myeloid leukemia (CML) patients in Turkey. Methods: Patients with newly diagnosed Philadelphia chromosome–positive CML in chronic phase (CML-CP; N = 112) received nilotinib 300 mg twice daily. The primary endpoint, which was the cumulative rate of major molecular response (MMR; BCR-ABL1 ≤ 0.1% on the International Scale [BCR-ABL1IS]) by 12 months, was previously reported (66.1% [80% CI, 59.7%–72.0%]). ClinicalTrials.gov identifier NCT01274351 Results: By 24 months, 83.0% of patients achieved MMR, and 50.9% achieved MR4.5 (BCR-ABL1IS ≤0.0032%). Safety results at 24 months were consistent with those at 12 months. No additional deaths or disease progressions to accelerated phase/blast crisis were observed between 12 and 24 months. Discussion: Treatment with nilotinib 300 mg twice daily for 2 years provided high MMR with a good safety/tolerability profile in newly diagnosed CML-CP patients in Turkey. Assessment of MMR across time points showed increasing rates through 18 months, after which as lower rate of increase was observed. The safety profile of nilotinib 300 mg twice daily with 24 months of follow-up was similar to that observed at 12 months, and no new safety concerns were identified. These efficacy and safety findings are consistent with the results from the 12-month analysis of this study and from previous nilotinib studies. These findings support nilotinib as an option for frontline treatment of CML-CP. Conclusion: Frontline nilotinib treatment provided sustained efficacy, with good tolerability, over 24 months in newly diagnosed CML-CP patients.
  • Küçük Resim
    Öğe
    Ibrutinib: From molecule to medicine
    (UHOD - Uluslararasi Hematoloji Onkoloji Dergisi, 2014) Ayyıldız, Orhan; Demirkan, Fatih; Göker, Hakan; Haznedaroğlu, İbrahim C.; İlhan, Osman; Kaynar, Leyla G.; Özdemir, Evren
    Bruton’s tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is a novel targeted-therapeutic agent modulating BCR, which serves as a covalent irreversible inhibitor of BTK. Ibrutinib significantly alters the composition of the tumor microenvironment in CLL, affecting soluble as well as cellular molecular elements without myelosupression. Ibrutinib is clinically developed as an orally administered anti-cancer agent with lead indications in relapse/refractory and in treatment-naïve patients with B-cell malignancies as a single agent. The clinical activities of Ibrutinib as a drug were shown in the B-cell malignancies, especially in patients with CLL, mantle cell lymphoma (MCL), and Waldenstrom’s macroglobulinemia (WM). Ibrutinib has generated the most extensive results so far in patients with CLL, predominately refractory or relapsed CLL where durable disease control as well as improved progression-free survival (PFS) and overall survival (OS) has been observed. The aim of this review is to outline the pharmacophysiological basis of Ibrutinib treatment as well as the current clinical experience based on the trials. The treatment algorithms of B-lymphoproliferative diseases will continue to be revised to a more personalized approach to treat with improved efficacy devoid of unnecessary toxicity.
  • [ X ]
    Öğe
    Retrospective evaluation of patients treated with dasatinib for philadelphia positive leukemias: Turkish experience of 16 months
    (2009) İlhan, Osman; Altıntaş, Abdullah; Saydam, Güray; Haznedaroğlu, İbrahim C.; Yavuz, Selim; Tombuloğlu, Murat; Gülbaş, Zafer
    Bu retrospektif çalışmada 114 KML hastasında ortalama tedavi süresi 7.94±4.53 aydı. Hastalar arasında hastalık durum dağılımı %78.1 kronik, %7.9 hızlanmış, %14 blastik faz şeklinde idi. Kronik, hızlanmış ve blastik fazlarda son imatinib dozları sırası ile 609.72±171.29, 714.29±106.90 ve 569.23±160.13 idi. Kronik ve hızlanmış fazlarda tam hematolojik cevap sırası ile %66.3 ve %44.4 olarak bulundu. Moleküler cevap RT-PCR’da bcr/abl transcript seviyeleri ile değerlenmişti. Tam moleküler cevap kronik fazda %27.0, hızlanmış fazda %11.1 ve blastik fazda %18.8 idi. Toplam 99 hastanın 77’si (%77.8) hayatta kalmıştı. Kaplan-Meier sağkalım analizinde 99 hastanın 16. ay genel sağkalım değeri %78 idi. Hastaların %69.2’sinde advers olay bildirilmezken, hastalık ilerlemesi ve evre 1-2 miyelosupresyon en sık bildirilmiş olan advers olaylardı. Hastaların çoğu tam hematolojik cevaba sahipti. Buna göre, dasatinib tedavisinin iyi tolere edildiği ve çoğunlukla hafif yan etkilerle birlikte olumlu çıktılar sağladığı söylenebilir.